Furthermore, when combined with both anti‐p53 Abs and CEA, the AUC of anti‐FIRΔexon2 Abs + CEA + anti‐p53 Abs (0.746) was higher than that of anti‐SOHLH1 Abs + CEA + anti‐p53 Abs (0.691), anti‐p53 Abs (0.702) or CEA (0.677) in patients with CRC (Figure 3E). This evidence concerns the gene TP53 and colorectal carcinoma.